By Chris Wack
Applied Therapeutics shares were up 11% to $1.40 after the company successfully completed a recent pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding its govorestat Galactosemia program.
The stock hit its 52-week high of $2.18 on May 1, and is down 1% in the past 12 months.
Based…
Read the full article here
